$315 Million is the total value of Sio Capital Management, LLC's 49 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MSAC | MEDICUS SCIENCES ACQUISITION | $22,998,000 | +1.2% | 2,323,000 | 0.0% | 7.31% | -14.4% | |
| VNDA | VANDA PHARMACEUTICALS INC | $4,831,000 | -9.4% | 488,965 | 0.0% | 1.54% | -23.3% | |
| UHS | UNIVERSAL HEALTH SERVICES INCcl b | $3,591,000 | -12.4% | 40,725 | 0.0% | 1.14% | -25.9% | |
| EUCRU | EUCRATES BIOMEDICAL ACQUISITION CORP.unit 10/23/2027 | $2,492,000 | 0.0% | 248,674 | 0.0% | 0.79% | -15.4% | |
| HSAQ | HEALTH SCIENCES ACQUISITIONS CORP 2 | $2,475,000 | -0.6% | 250,000 | 0.0% | 0.79% | -15.9% | |
| AGLE | AEGLEA BIO THERAPEUTICS INC | $2,456,000 | +4.2% | 4,668,536 | 0.0% | 0.78% | -12.0% | |
| MODULAR MEDICAL INC | $2,366,000 | -20.5% | 574,352 | 0.0% | 0.75% | -32.7% | ||
| CBAY | CYMABAY THERAPEUTICS INC | $1,945,000 | +18.7% | 555,610 | 0.0% | 0.62% | +0.3% | |
| RENOVACOR INC | $1,854,000 | +24.3% | 735,908 | 0.0% | 0.59% | +5.2% | ||
| MRUS | MERUS NV | $1,762,000 | -11.5% | 87,953 | 0.0% | 0.56% | -25.1% | |
| AFMD | AFFIMED NV | $1,691,000 | -25.6% | 821,065 | 0.0% | 0.54% | -37.1% | |
| ISEE | IVERIC BIO INCput | $1,550,000 | +86.5% | 86,400 | 0.0% | 0.49% | +58.0% | |
| TYRA BIOSCIENCES INC | $1,337,000 | +22.9% | 152,159 | 0.0% | 0.42% | +3.9% | ||
| SVRA | SAVARA INC | $1,327,000 | +1.9% | 856,428 | 0.0% | 0.42% | -13.7% | |
| ANIP | ANI PHARMACEUTICALS INC | $1,286,000 | +8.3% | 40,000 | 0.0% | 0.41% | -8.3% | |
| MBRX | MOLECULIN BIOTECH INC | $1,099,000 | -26.9% | 1,036,853 | 0.0% | 0.35% | -38.2% | |
| FUSN | FUSION PHARMACEUTICALS INC | $784,000 | +20.8% | 260,448 | 0.0% | 0.25% | +2.0% | |
| CNTB | CONNECT BIOPHARMA HOLDINGS LTDads | $771,000 | +48.3% | 597,678 | 0.0% | 0.24% | +25.6% | |
| ASLN | ASLAN PHARMACEUTICALS LTDads | $761,000 | +21.0% | 1,270,758 | 0.0% | 0.24% | +2.5% | |
| ELEV | ELEVATION ONCOLOGY INC | $406,000 | -19.4% | 359,731 | 0.0% | 0.13% | -31.7% | |
| NXTC | NEXTCURE INC | $358,000 | -41.4% | 130,000 | 0.0% | 0.11% | -50.2% | |
| CMAX | CAREMAX INC | $218,000 | +94.6% | 30,741 | 0.0% | 0.07% | +64.3% | |
| VINC | VINCERX PHARMA INC | $141,000 | +4.4% | 102,049 | 0.0% | 0.04% | -11.8% | |
| NYXOAH SA | $101,000 | -31.8% | 16,110 | 0.0% | 0.03% | -42.9% | ||
| HUMACYTE INC*w exp 09/21/202 | $58,000 | +28.9% | 49,998 | 0.0% | 0.02% | +5.9% | ||
| RENOVACOR INC*w exp 99/99/999 | $37,000 | +8.8% | 400,000 | 0.0% | 0.01% | -7.7% | ||
| NLTX | NEOLEUKIN THERAPEUTICS INC | $25,000 | -35.9% | 38,312 | 0.0% | 0.01% | -46.7% | |
| CMAXW | CAREMAX INC*w exp 06/08/202 | $23,000 | +155.6% | 12,808 | 0.0% | 0.01% | +133.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.